Aims-To test the sensitivity of strains of Campylobacter species isolated from humans in England and Wales against a range of antimicrobial agents for the purpose of monitoring therapeutic eYcacy and as an epidemiological marker. Methods-An agar dilution breakpoint technique was used to screen isolates against ampicillin, chloramphenicol, gentamicin, kanamycin, neomycin, tetracycline, nalidixic acid, ciprofloxacin, and erythromycin. Minimal inhibitory concentrations (MIC) were also determined for a sample of quinolone resistant strains.
The significance of acute enteric disease caused by Campylobacter species was only appreciated in the 1970s, with the advent of improved isolation methods. 1 Campylobacter spp have been the commonest reported cause of acute bacterial enteritis in England and Wales since 1981, as measured by reports to the Public Health Laboratory Service (PHLS) Communicable Disease Surveillance Centre (CDSC), and there were over 50 000 cases reported in 1997. 2 Several studies have indicated that more than 90% of infections are caused by to C jejuni, with C coli representing most of the remainder. C lari comprises < 1% of the strains isolated, with other species, such as C upsaliensis and C fetus, only occasionally seen in clinical isolates. 3 Although antibiotic treatment is not advised in the majority of cases of diarrhoeal disease caused by Campylobacter spp, in severe or prolonged illness the use of erythromycin or ciprofloxacin is recommended. 4 Erythromycin resistance in clinical isolates of C jejuni is still believed to be rare, although it has been more commonly reported in C coli strains. 5 Reina et al suggested that there was also a significant increase in erythromycin resistance in quinolone resistant strains, 6 Since April 1997, campylobacters isolated from humans with diarrhoeal disease in Wales and north west England have been referred to the Laboratory of Enteric Pathogens for typing. In this paper we describe the incidence of antimicrobial resistance in these isolates.
Methods

CULTURE AND IDENTIFICATION
Isolates from humans with acute gastrointestinal infections were sent to the Laboratory of Enteric Pathogens. All isolates were plated onto Columbia blood agar and grown in a variable atmosphere incubator (VAIN, Don Whitley) in an atmosphere of 87% nitrogen, 5% oxygen, 3% hydrogen, and 5% carbon dioxide for 48 hours. Six discrete colonies were then picked, pooled, and plated onto a second Columbia blood agar plate. These were incubated for 24 hours in the VAIN and growth from this plate harvested to prepare cell suspensions for further tests. All strains received were identified to species level, as well as being tested for drug resistance.
TESTING FOR RESISTANCE TO ANTIMICROBIAL
DRUGS
An agar incorporation method was used for drug resistance screening and determination of minimal inhibitory concentrations (MICs).
11
The antimicrobials tested were incorporated into Iso-Sensitest agar, which contained 5% laked horse blood. The breakpoints used are shown in table 1. These breakpoints are those published by the British Society of Antimicrobial Chemotherapy (BSAC) 12 except for that of erythromycin. No published guidelines exist for erythromycin testing in campylobacter. The BSAC does not recommend a concentration for any Gram negative organism. The National Committee for Clinical Laboratory Standards (NCCLS), in the USA, recommends that intermediate resistance to erythromycin for most organisms should be defined as between 1 and 4 mg/l and high resistance as > 8 mg/l. 13 For the purpose of this stufy a breakpoint of 4 mg/l was accepted, to include all those strains showing resistance. This single breakpoint screening allows large numbers of strains to be examined for drug resistance in a timely manner suited to the high level of work experienced in a reference laboratory.
Trimethoprim was included in the screening, although all campylobacter strains are intrinsically resistant, as a check on identity; trimethoprim resistance was therefore not included in this analysis.
For drug resistance screening, a suspension equivalent to a turbidity of McFarland 1 was made in a brain-heart infusion broth. After incubation at 37°C for four hours, 0.5 ml of each broth was then loaded into one well of a 36 well block for use with a Denley multipoint inoculator. Each antibiotic plate was inoculated with 30 strains and six control strains using a multipoint inoculator (table 1) . For controls, National Collection of Type Cultures (NCTC) strains were used, except for C8436 which is a multiresistant strain of C jejuni serotype HS50 isolated from a patient in 1997. The plates were incubated for 48 hours in the VAIN at 37°C and growth on the plates was scored in comparison with a non-selective control plate.
Results
The majority of isolates (93%) were C jejuni. Of the remainder, 6.5% were C coli and 0.5% C lari. The incidence of drug resistance in campylobacters in these strains is shown in table 2. Strains resistant to four or more of the drugs were termed multiresistant. Drug resistance to one or more drugs was detected in over 50% of strains; multiresistance was found in 11% of C jejuni strains but was more common in C coli (20%) and C lari (60%), although C lari are constitutively resistant to quinolones.
In C jejuni, 34% of strains tested were resistant to ampicillin, but less than 2% of strains were resistant to aminoglycosides and erythromycin. All 43 isolates of C jejuni resistant to kanamycin were also resistant to tetracyclines. Resistance to kanamycin was common in those strains of C lari tested (60%), but tetracycline resistance was less common (12%). C coli, which make up 6.5% of the total strains tested, were generally more resistant. Erythromycin resistance was seen in only 1.0% of C jejuni, but in 12.8% of C coli strains. All 25 strains of C lari tested were sensitive to erythromycin.
C jejuni and C coli can be divided into three groups with respect to quinolone resistance, as is shown by full MICs done on a subset of 60 isolates (table 3) . This set was selected as a sample of 20 strains each of those resistant to ciprofloxacin and nalidixic acid, nalidixic acid only, or sensitive to both, by primary breakpoint analysis. Fully sensitive strains (88.3%) were sensitive to nalidixic acid at 16 mg/l and ciprofloxacin at 1 mg/l. An intermediate group comprising 4 .3% of strains appeared as nalidixic acid resistant and ciprofloxacin sensitive in the routine screen (table 2). These had an MIC against nalidixic acid of 32 to 64 mg/l and a ciprofloxacin MIC of 1 mg/l. Strains that had a high level of resistance (> 256 mg/l for nalidixic acid, > 16 mg/l for ciprofloxacin) accounted for 10.5% of the C jejuni tested and 21.8% of the C coli.
Resistance to both quinolone drugs tested was more frequent in C coli.
Discussion
In C coli, 13% of strains showed resistance to erythromycin, while only 1% of C jejuni were resistant. This would have a significant bearing on treatment of those infections not caused by C jejuni. Metronidazole has been suggested as a possible alternative treatment in some cases, but this antibiotic is only eVective when in an anaerobic atmosphere, this makes testing its eYcacy against campylobacter strains diYcult, as they will only grow in the presence of low levels of oxygen. C jejuni and C coli were predominantly sensitive to aminoglycosides. Of the 25 strains of C lari tested, 15 were resistant to kanamycin, with one also resistant to neomycin. All 43 C jejuni strains which were resistant to kanamycin were also resistant to tetracyclines. This supports the hypothesis that kanamycin resistance is encoded on a plasmid that also mediates tetracycline resistance.
14 In this study, strains that were resistant to quinolone drugs can be considered in two groups, depending on their MIC. High level resistance predominates, with a further 4.3% of isolates showing intermediate resistance. Up to 20% of patients treated with ciprofloxacin may relapse due to the emergence of resistance with MICs of 32 mg/l or higher in the infecting strain. 7 It is therefore wise to avoid treating with ciprofloxacin in those cases where the MIC is already raised. The current British Society for Antimicrobial Chemotherapy (BSAC) recommended breakpoint for low level ciprofloxacin resistance is 1 mg/l. 12 The closeness of the breakpoint to the sensitive MIC may falsely indicate sensitive strains. The MIC level at which resistance is reported should perhaps be lowered, to encompass all strains showing an increased MIC. Recent sequence analysis of quinolone resistance mutations has shown that a substitution of Thr-86-Ile in the gyrA gene and a Arg-139-Gln substitution in the parC gene of C jejuni is associated with quinolone resistance. 15 This detailed genetic analysis of resistant mutants will lead to a greater understanding of the evolution and epidemiology of drug resistance in campylobacter.
Reina et al divided nalidixic acid resistant C jejuni strains into two classes 6 : type 1, resistant to all quinolones (ciprofloxacin MIC > 4 mg/l, nalidixic acid MIC > 32 mg/l), and type 2, only resistant to acidic quinolones (nalidixic acid MIC > 32 mg/l, ciprofloxacin MIC < 4 mg/l); they do not suggest a mechanism for this resistance. Type 1 predominates in Spain, although figures were only quoted for those strains also resistant to erythromycin (where 8% of all strains were type 2 and 68% type 1). In the present study, 28% of nalidixic acid resistant strains fall into type 2, with an MIC against nalidixic acid of between 32 mg/l and 64 mg/l and an MIC against ciprofloxacin of < 4 mg/l.
The link between the use of fluoroquinolones in veterinary medicine and emerging resistance in human isolates should be explored more thoroughly, as it may have serious consequences on treatment of human disease. Concern has been expressed over the rate of ciprofloxacin resistance in Salmonella typhimurium DT104 isolated from humans (14% in 1996) 16 ; the rate in Campylobacter spp (11.7%) is comparable and there are serious concerns over the apparent rapid increase. 7 In 1992, the Expert Group on Animal FeedingstuVs 17 recommended that antibiotics that could lead to cross resistance to those used in human medicine should not be used as growth promoters, and that their prophylactic use in animals should be reconsidered. This sentiment has been reiterated by the Standing Medical Advisory Committee 18 subgroup on antimicrobial resistance, which recommend that use of antimicrobial agents in veterinary practice should be guided by the same principles as in human prescribing-that is, that "antimicrobial agents be used only when likely to yield a specific health benefit."
